<?xml version="1.0" encoding="UTF-8"?>
<p>Furthermore, as Farzan added, it does not mutate rapidly for an RNA virus because, unusually for this category, it has a proof‐reading function in its polymerase 
 <xref rid="embr202050334-bib-0003" ref-type="ref">3</xref>. “In short, a vaccine, and especially a vaccine targeted in part to the receptor‐binding domain of the 2019‐nCoV entry protein, the Spike or S protein, should be effective”, he said. As this protein is protected against mutation, a vaccine would not need regular updates, unlike seasonal influenza vaccines.
</p>
